MYLANTA TRADEMARK INFRINGEMENT SUIT FILED AGAINST GUARDIAN DRUG
This article was originally published in The Tan Sheet
MYLANTA TRADEMARK INFRINGEMENT SUIT FILED AGAINST GUARDIAN DRUG by Johnson & Johnson-Merck, alleging that Guardian's Myacid private-label antacid products are "confusingly similar to [J&J- Merck's] well-known Mylanta trademark." Filed in the U.S. District Court in the Eastern District of Pennsylvania on Feb. 10, the complaint demands that Guardian be preliminarily and permanently enjoined from "manufacturing, selling, distributing, advertising or promoting antacid products under the name Myacid or any other name that is confusingly similar to Mylanta."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC